Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer [0.03%]
碳酸酐酶十二抑制可克服P-糖蛋白介导的药物抗性：癌症中可能的新联合疗法
Kathryn F Tonissen,Sally-Ann Poulsen
Kathryn F Tonissen
Intrinsic or acquired resistance to chemotherapy is a major hurdle in the treatment of cancer. One of the key mechanisms of resistance is the overexpression of the drug efflux transporter P-glycoprotein (Pgp). Pgp overexpression renders a l...
Siraj Shaikh,Javed Shaikh,Yusufi Sadia Naba et al.
Siraj Shaikh et al.
Curcumin, a polyphenol, has a wide range of biological properties such as anticancer, antibacterial, antitubercular, cardioprotective and neuroprotective. Moreover, the anti-proliferative activities of Curcumin have been widely studied agai...
ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome [0.03%]
ABCA1与获得性化疗耐药的发生相关并可预测卵巢癌预后不良
Wanqi Wang,Noor A Lokman,Tannith M Noye et al.
Wanqi Wang et al.
Aim: This study investigated the ATP binding cassette (ABC) transporter (ABCA1, ABCB1, ABCB3, ABCC2 and ABCG2) expression in high grade serous ovarian cancer (HGSOC) tissues, cell lines and primary cells to determine their potential relatio...
Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer [0.03%]
旧犬新把戏：重新激活的发育信号通路在癌症中调节ABCB1和化学抗性
Wing-Kee Lee,Thévenod Frank
Wing-Kee Lee
Oncogenic multidrug resistance (MDR) is a multifactorial phenotype intimately linked to deregulated expression of detoxification transporters. Drug efflux transporters, particularly the MDR P-glycoprotein ABCB1, represent a central mechanis...
Norman Fultang,Madhuparna Chakraborty,Bela Peethambaran
Norman Fultang
Triple Negative Breast Cancer (TNBC) is the most lethal subtype of breast cancer. Despite the successes of emerging targeted therapies, relapse, recurrence, and therapy failure rates in TNBC significantly outpace other subtypes of breast ca...
Joanna Kopecka,Chiara Riganti
Joanna Kopecka
History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications [0.03%]
卵巢癌腹腔内铂类药物治疗的历史与未来展望
Franco Muggia,Andrea Bonetti
Franco Muggia
Intraperitoneal (IP) delivery of cisplatin was developed in the 1970s based on a strong pharmacologic rationale and rodent models. Its advantage over intravenous (IV) administration was supported initially by observational studies in treati...
Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy [0.03%]
用于纳米医学联合化疗的药理学优化的抗癌药物脂质体共封装技术
Alberto Gabizon,Patricia Ohana,Yasmine Amitay et al.
Alberto Gabizon et al.
Aim: Co-encapsulation of anti-cancer agents in pegylated liposomes may provide an effective tool to maximize efficacy of combined drug therapy by taking advantage of the long circulation time, passive targeting, and reduced toxicity of lipo...
Richard Callaghan,Mary Board
Richard Callaghan
Cancer cells are highly proliferative, invasive, metastatic and initiate angiogenesis. These activities demand plentiful energy and bountiful stores of anabolic precursors, a situation that puts significant strain on metabolic pathways and ...
Roberto Gutierrez,Timothy R O&#x;Connor
Roberto Gutierrez
DNA direct reversal repair (DRR) is unique in that no DNA synthesis is required to correct the error and therefore repair via such mechanisms are error-free. In humans, DRR is carried out by two different pathways: the O6-methylguanine-DNA ...